LLY Eli Lilly and Company

1351.20USD-2.28%Mkt Cap: 1.20T USDP/E: 43.85

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, incl…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap1.20T USD
Enterprise Value1.28T USD
Revenue (TTM)86.46B USD
Gross Profit54.13B USD
Net Income (TTM)20.64B USD
Revenue/Share96.75 USD
Last Price1351.20 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees50.0K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - General
ISIN—
Valuation
P/E (Trailing)43.85
P/E (Forward)26.56
PEG1.28
EV/EBITDA27.45
EV/Revenue14.76
P/S13.92
P/B29.90
EPS (TTM)30.81 USD
EPS (Forward)50.80 USD
52W Range
850.5180% of range1475.25
52W High1475.25 USD
52W Low850.51 USD
Profitability
Gross Margin83.04%
Oper. Margin51.25%
EBITDA Margin53.77%
Profit Margin31.67%
ROE77.78%
ROA18.35%
ROIC38.56%
ROCE38.44%
Growth
Revenue Growth38.60%
Earnings Growth16.30%
Cash Flow & Leverage
Operating CF16.81B USD
CapEx (TTM)10.85B USD
FCF Margin10.81%
FCF Yield0.78%
Net Debt44.62B USD
Net Debt/EBITDA0.96
Net Debt/FCF4.78
Balance Sheet
Debt/Equity1.60
Current Ratio1.39
Quick Ratio0.64
Book Value/Sh45.19 USD
Cash/Share5.48 USD
Dividends
Fwd Div Rate6.92 USD
Trail. Div Rate6.69 USD
Div. Yield0.50%
5Y Avg Yield0.75%
Payout Ratio21.71%
Ex-Div DateNov 13, 2026
Pay DateDec 10, 2026
Splits
Last Split2:1
Split DateOct 16, 1997
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)1468.57 USD
Upside (mean)+8.7%
Target Range940.00 USD – 1700.00 USD
940.00+8.7% to mean1700.00
# Analysts29
Ownership
Shares Out.890.75M
Float888.43M
Insiders0.19%
Institutions85.59%
Short Interest
Short Ratio2.8d
Short % Float0.81%
Short % Out.0.81%
Shares Short7.21M
Short (prev mo.)7.04M
Technical
SMA 501246.72 (+8.4%)
SMA 2001111.30 (+21.6%)
Beta0.39
S&P 52W Chg12.08%
Avg Vol (30d)2.64M
Avg Vol (10d)3.18M
Technical Indicators
RSI (14)50.2
MACD39.8303
MACD Signal50.0510
MACD Hist.-10.2207
BB Upper1495.68 USD
BB Middle1380.37 USD
BB Lower1265.06 USD
BB Width16.71%
ATR (14)43.30 USD
Vol Ratio (20d)1.09x

About Eli Lilly and Company (NYSE: LLY)

›

Eli Lilly and Company (NYSE: LLY) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 50,000 employees.

The shares were at 1351.20 USD on 19 November 2026, up 32.2% over 52 weeks. Its 52-week range is 850.51 USD to 1475.25 USD: the price is 8.4% below the high and 58.9% above the low.

At a market capitalisation of 1.20T USD, it trades at 43.9 times trailing earnings and 26.6 times forward earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 25.4, a premium of 72% for LLY. It pays a dividend yielding 0.50% (it pays out 22% of its earnings), against a median of 2.55% among the dividend payers in that peer group.

Eli Lilly and Company reports return on equity of 77.8%, an operating margin of 51.3% and revenue up 38.6% year over year.

Its debt exceeds its cash by 44.62B USD, a debt-to-equity ratio of 1.60. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 29 analysts cover the stock, with an average rating of Buy; their mean price target of 1468.57 USD is 8.7% above the current price. The next earnings report is expected on 3 February 2027.